iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoids The first target cancer type of PHAGERIA® technology is colorectal cancer (CRC) BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ — iNtRON Biotechnology (“iNtRON”,…